These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 28486411)

  • 41. The expression and clinical significance of GTP-binding RAS-like 3 (ARHI) and microRNA 221 and 222 in prostate cancer.
    Lin D; Cui F; Bu Q; Yan C
    J Int Med Res; 2011; 39(5):1870-5. PubMed ID: 22117988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epigenetic mechanisms in the biology of prostate cancer.
    Schulz WA; Hoffmann MJ
    Semin Cancer Biol; 2009 Jun; 19(3):172-80. PubMed ID: 19429481
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deciphering the genetic and epigenetic architecture of prostate cancer.
    Nazir SU; Mishra J; Maurya SK; Ziamiavaghi N; Bodas S; Teply BA; Dutta S; Datta K
    Adv Cancer Res; 2024; 161():191-221. PubMed ID: 39032950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells.
    Chu M; Chang Y; Guo Y; Wang N; Cui J; Gao WQ
    PLoS One; 2015; 10(4):e0116197. PubMed ID: 25860954
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [MicroRNA in prostate cancer].
    Nakagawa M
    Nihon Rinsho; 2014 Dec; 72(12):2224-8. PubMed ID: 25518362
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Molecular mechanisms involved in epigenetic alterations in cancer].
    Toyota M; Suzuki H; Nishizaka T; Sato A; Yamashita T
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1650-3. PubMed ID: 20841926
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The evolving epigenome.
    Weichenhan D; Plass C
    Hum Mol Genet; 2013 Oct; 22(R1):R1-6. PubMed ID: 23900077
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion.
    Björkman M; Östling P; Härmä V; Virtanen J; Mpindi JP; Rantala J; Mirtti T; Vesterinen T; Lundin M; Sankila A; Rannikko A; Kaivanto E; Kohonen P; Kallioniemi O; Nees M
    Oncogene; 2012 Jul; 31(29):3444-56. PubMed ID: 22120715
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epigenetic and Epitranscriptomic Control in Prostate Cancer.
    López J; Añazco-Guenkova AM; Monteagudo-García Ó; Blanco S
    Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205419
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The potential of DNA modifications as biomarkers and therapeutic targets in oncology.
    Jankowska AM; Millward CL; Caldwell CW
    Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment.
    Basse C; Arock M
    Int J Cancer; 2015 Dec; 137(12):2785-94. PubMed ID: 25410431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Knowledge of epigenetic influence for prostate cancer therapy.
    Watanabe M; Takagi A; Matsuzaki T; Kami D; Toyota M; Hirokawa Y; Shiraishi T
    Curr Cancer Drug Targets; 2006 Sep; 6(6):533-51. PubMed ID: 17017872
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics.
    Gordanpour A; Nam RK; Sugar L; Seth A
    Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):314-9. PubMed ID: 22333688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting epigenetics for the treatment of prostate cancer: recent progress and future directions.
    Lin J; Wang C; Kelly WK
    Semin Oncol; 2013 Jun; 40(3):393-401. PubMed ID: 23806502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer.
    Singh AK; Chandra N; Bapat SA
    Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integrated Analysis Reveals together miR-182, miR-200c and miR-221 Can Help in the Diagnosis of Prostate Cancer.
    Gu Y; Lei D; Qin X; Chen P; Zou YM; Hu Y
    PLoS One; 2015; 10(10):e0140862. PubMed ID: 26484677
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma.
    Syren P; Andersson R; Bauden M; Ansari D
    Scand J Gastroenterol; 2017; 52(6-7):668-673. PubMed ID: 28301276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer.
    Roy P; Singh KP
    Int Rev Cell Mol Biol; 2023; 380():173-210. PubMed ID: 37657858
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epigenetic biomarkers in urological tumors: A systematic review.
    Jerónimo C; Henrique R
    Cancer Lett; 2014 Jan; 342(2):264-74. PubMed ID: 22198482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
    Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
    Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.